Albireo to Showcase New Data at AASLD The Liver Meeting®

– Seven abstracts accepted, including one oral presentation highlighting long-term data demonstrating Bylvay® (odevixibat) durable efficacy in patients...

Related Keywords

United States ,Germany ,United Kingdom ,Massachusetts ,Washington ,Belgium ,Gothenburg ,Vastra Gotalands Lan ,Sweden ,Italy ,Boston ,Austria ,Spain ,Northern Ireland ,Craigavon ,London ,City Of ,Scotland ,Henkjanj Verkade ,Colleen Alabiso ,Lorenzo Dantiga ,Lance Buckley ,Richardj Thompson ,Franciscoj Caballero Camino ,Intrahepatic Cholestasis ,Azienda Ospedaliera Papa Giovanni ,Georg Friedrich Vogel ,King College London ,Albireo Pharma Inc ,Department Of Paediatric Hepatology ,University Of Innsbruck ,Department Of Paediatrics ,European Commission ,Institute Of Liver ,Nasdaq ,Exchange Commission ,Beatrix Children Hospital University Medical Centre Groningen ,Astrazeneca ,Healthcare Products Regulatory Agency ,University Of Groningen ,Access Program ,American Association ,Liver Diseases ,Native Liver Survival ,Progressive Familial Intrahepatic ,Liver Studies ,Pediatric Liver ,Pooled Data ,Beatrix Children ,University Medical Centre Groningen ,Poster Session ,Long Term Efficacy ,Progressive Familial Intrahepatic Cholestasis ,College London ,Odevixibat Treatment ,Recurrent Episodic Cholestasis ,Biallelic Mutations ,Retrospective Case ,Angelo Di Giorgio ,Hospital Papa Giovanni ,Odevixibat Therapy ,Assistant Professor ,Medical University ,Innsbruck ,Serum Bile Acid Levels ,Pruritus Scores ,Growth Over Time ,Odevixibat Responders ,Lorenzod Antiga ,Paediatric Hepatology ,Urinary Excretion ,Bile Acids ,Halts Liver Disease Progression ,Obstructed Mice ,Instituto De Investigaci ,Sanitaria Biodonostia ,San Sebasti ,Basque Country ,United Kingdom Medicines ,Test Abnormalities ,Soluble Vitamin ,Open Label Extension ,Private Securities Litigation Reform Act ,Expanded Access Program ,Annual Report ,Nasdaq Albo ,Albireo Pharma ,Nc ,